Research Nester released a report titled “Cystic Fibrosis Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global cystic fibrosis drugs market in terms of market segmentation by drug class, by route of administration, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Cystic fibrosis is a genetic disorder which affects various organs of the body and impacts their functioning by damaging the cells which produce body secretions such as sweat, mucus and digestive juices. The cystic fibrosis drugs market is anticipated to record a CAGR of around 17% over the forecast period, i.e., 2020-2028. The market is segmented by drug class, by route of administration, by distribution channel and by region. The segment for drug class is further segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, CFTR modulators and others, out of which, the CFTR modulators segment is anticipated to hold the largest share in the cystic fibrosis drugs market on account of high usage of these drugs for the treatment of cystic fibrosis as compared to other drugs.

On the basis of region, the cystic fibrosis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to hold the largest share in the market on account of improved healthcare infrastructure in the region which improves the quality of research and development in laboratories. The market in Asia Pacific is predicted to grow at the highest rate as a result of entrance of leading pharmaceutical companies and drug manufacturers in the region as well as the growing awareness among people about cystic fibrosis.

Rising Number Of Drugs Being Developed To Drive The Market Growth

Presently, several drugs have been approved for the treatment of cystic fibrosis and several others are in the developmental phase or are undergoing clinical trials. This is predicted to significantly contribute towards the market growth in the coming years. However, the high cost of cystic fibrosis drugs prevents a large majority of consumers from buying them, especially those belonging to the low and middle income countries. This is estimated to hinder the market growth.

This report also provides the existing competitive scenario of some of the key players of the global cystic fibrosis drugs market which includes company profiling of AbbVie, Vertex Pharmaceuticals, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Novartis AG, Actavis, Pharmaxis Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc. and Aridis Pharmaceuticals Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global cystic fibrosis drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.